INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $5,735,946 | +66.2% | 108,389 | +46.2% | 0.32% | +100.0% |
| Q3 2022 | $3,451,000 | -57.7% | 74,155 | -48.1% | 0.16% | -51.4% |
| Q2 2022 | $8,154,000 | +0.8% | 142,868 | +8.0% | 0.33% | +13.7% |
| Q1 2022 | $8,092,000 | +30.1% | 132,241 | +11.3% | 0.29% | +32.6% |
| Q4 2021 | $6,221,000 | +73.7% | 118,854 | +23.7% | 0.22% | +45.4% |
| Q3 2021 | $3,582,000 | -30.2% | 96,072 | -23.6% | 0.15% | -28.3% |
| Q2 2021 | $5,133,000 | +91.7% | 125,773 | +59.4% | 0.21% | +92.7% |
| Q1 2021 | $2,678,000 | +34.5% | 78,888 | +26.0% | 0.11% | +44.7% |
| Q4 2020 | $1,991,000 | -2.4% | 62,588 | -21.3% | 0.08% | -20.8% |
| Q3 2020 | $2,041,000 | -1.9% | 79,486 | -2.0% | 0.10% | -19.3% |
| Q2 2020 | $2,081,000 | +474.9% | 81,085 | +243.8% | 0.12% | +310.3% |
| Q1 2020 | $362,000 | -89.9% | 23,582 | -77.5% | 0.03% | -85.4% |
| Q4 2019 | $3,600,000 | – | 104,925 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |